ClinicalTrials.gg
TerminatedNCT02038049Updated Jan 5, 2021Results posted

A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis

A Phase 2 interventional study of VAY736 and Placebo in Relapse Remitting Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Terminated at 5 sites in 3 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-01-05.

Primary conditionMultiple Sclerosis, Relapsing-RemittingRegistry: Multiple SclerosisReclassifiedWhy we changed it
Registry
Multiple Sclerosis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Multiple Sclerosis, Relapsing-Remitting
Why
  1. The study's title name Multiple Sclerosis, Relapsing-Remitting, a narrower term within Multiple Sclerosis.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Why this study was terminated
The study recruitment was terminated based on strategic considerations after 8 patients were enrolled.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies in Multiple Sclerosis, Relapsing-Remitting by Novartis — 1 open to participants now, 4 under way, none of them phase 3. Multiple Sclerosis, Relapsing-Remitting · Novartis.

Enrollment
24th of 26
8 · median 147
Started
2013
with 2 others
Phase 2
6 of 34
none open now
Registered
20th of 34
by date

Among the 34 studies in Multiple Sclerosis, Relapsing-Remitting by Novartis, this one is the 24th largest by enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2013, is one of 6 in phase 2, and was the 20th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

1 of the 34 studies in Multiple Sclerosis, Relapsing-Remitting by Novartis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Multiple Sclerosis, Relapsing-Remitting by Novartis, or all of them as a file.
02

Study summary

This was a randomized, partially blinded, placebo-controlled, non-confirmatory study to assess the effects of a single infusion of VAY736 on disease activity as measured by brain MRI scans in patients with relapsing-remitting multiple sclerosis (RRMS).

Read the detailed description

The study was planned to be conducted in approximately 96 patients. However, after enrolling 8 patients, the recruitment was terminated based on strategic considerations.

03

Conditions studied

  • Relapse Remitting Multiple Sclerosis

Browse trials for

Keywords

  • Multiple Sclerosis
  • Relapsing-Remitting Multiple Sclerosis
  • Magnetic Resonance Imaging
  • VAY736
  • Lanalumab
  • monoclonal antibody
  • gadolinium [Gd]-enhancing lesions
  • B-Cell
04

In context

Multiple Sclerosis, Relapsing-Remitting Reclassified

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

This study's enrollment of 8 is below the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Compared within Multiple Sclerosis, Relapsing-Remitting, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Multiple Sclerosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion criteria:

  • Male and female patients aged 18 to 55 years.
  • Diagnosis of MS as defined by the 2010 revised McDonald criteria (Polman et al 2011).
  • A relapsing-remitting course of disease with:

    • at least 1 documented relapse during the previous 12 months (but not within 30 days prior to randomization ), or
    • a positive Gd-enhancing lesion on brain MRI scan at screening.
  • An Expanded Disability Status Scale (EDSS) score of 0-5.0 inclusive at screening.
  • No evidence of a relapse within 30 days prior to randomization.

Key exclusion criteria:

  • A manifestation of another type of MS other than RRMS.
  • Findings on screening or baseline brain MRI inconsistent with the diagnosis of MS.
  • History of chronic disease of the immune system other than MS, or a known immunodeficiency syndrome.
  • Score "yes" on item 4 or item 5 of the Suicidal Ideation section of the C-SSRS, if this ideation occurred in the past 6 months, or "yes" on any item of the Suicidal Behavior section, except for the "Non-Suicidal Self-Injurious Behavior" (item also included in the Suicidal Behavior section), if this behavior occurred in the past 2 years.
  • Women of and Pregnant or nursing (lactating) women.
  • Screening CBC (complete blood count) laboratory values as follows:
  • levels below 10.0 g/dL
  • Total leukocyte count less than 3,000 cells/µL
  • Neutropenia, defined as less than 1500 cells/mm3
  • less than 100,000/µL
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    VAY736

    Intravenous infusion of VAY736

    Drug: VAY736

  • Placebo comparator
    Placebo to VAY736

    Matching placebo (infusion bag) administered intravenously. Placebo randomized patients were offered optional VAY736 administration after week 16

    Drug: Placebo

Interventions

  • DrugVAY736

    Single intravenous infusion of VAY736 (10 mg/kg)

    Also known as: Lanalumab

  • DrugPlacebo

    Placebo to VAY736

07

What researchers measure

Primary outcomes

  1. Number of New T1-weighted Gadolinium (Gd)-Enhancing Lesions at Weeks 8, 12 and 16

    The effect of VAY736, compared to placebo on the cumulative number of new gadolinium \[Gd\]-enhancing lesions on T1-weighted brain MRI scans in relapsing-remitting multiple sclerosis (RRMS) patient population at weeks 8, 12 and 16. Only descriptive statistics performed.

    Time frame: Week 8, Week 12, Week 16

Secondary outcomes

  1. Number of All T1-weighted Gadolinium (Gd)-Enhancing Lesions at Weeks 4, 8, 12 and 16

    Magnetic resonance imaging (MRI) scanning of the brain was performed at screening/baseline, week 4, week 8, week 12 and week 16 to assess all T1-weighted Gadolinium (Gd) enhancing lesions. Each MRI scan was reviewed by a local neuro-radiologist. Only descriptive statistics performed.

    Time frame: Week 4, Week 8, Week 12, Week 16

  2. Number of New T1-weighted Gadolinium (Gd)-Enhancing Lesions at Weeks 4, 8, 12 and 16

    Magnetic resonance imaging (MRI) scanning of the brain was performed at screening/baseline, week 4, week 8, week 12 and week 16 to assess all new T1-weighted Gadolinium (Gd) enhancing lesions. Each MRI scan was reviewed by a local neuro-radiologist. Only descriptive statistics performed.

    Time frame: Week 4, Week 8, Week 12, Week 16

  3. Number of New or Enlarging T2-weighted Gadolinium (Gd)-Enhancing Lesions at Weeks 4, 8, 12 and 16

    Magnetic resonance imaging (MRI) scanning of the brain was performed at screening/baseline, week 4, week 8, week 12 and week 16 to assess T2 hyperintense lesions (new or enlarging T2-weighted lesions). Each MRI scan was reviewed by a local neuro-radiologist. Only descriptive statistics performed.

    Time frame: Week 4, Week 8, Week 12, Week 16

  4. T2 Burden of Disease (Total Volume of T2-weighted Lesions) at Weeks 4, 8, 12 and 16.

    Magnetic resonance imaging (MRI) scanning of the brain was performed at screening/baseline, week 4, week 8, week 12 and week 16 to assess T2 burden of disease. Each MRI scan was reviewed by a local neuro-radiologist. Only descriptive statistics performed.

    Time frame: Week 4, Week 8, Week 12, Week 16

  5. Number of Subjects Without Any New MRI Disease Activity at Weeks 4, 8, 12 and 16.

    Magnetic resonance imaging (MRI) scanning of the brain was performed at screening/baseline, week 4, week 8, week 12 and week 16 to assess patients without any new MRI disease activity (no new Gd-enhancing lesions nor new or enlarging T2 lesions). Each MRI scan was reviewed by a local neuro-radiologist. Only descriptive statistics performed.

    Time frame: Week 4, Week 8, Week 12, Week 16

  6. Proportion of Relapse-free Patients Over the 16 Weeks of the Treatment Period.

    A relapse is defined as the appearance of a new neurological abnormality, or worsening of previously stable, or improving pre-existing neurological abnormality, separated by at least 30 days from the onset of a preceding clinical demyelinating event. The abnormality must be present for at least 24 hours and occur in the absence of fever (\<37.5 C) or infection. A relapse was considered confirmed when confirmed by an Extended disability status scale (EDSS)-certified physician who was not involved in the treatment of the patient, was blinded to treatment allocation, and had no access to patient medical records. It was recommended that this occurs within 5 days of the onset of symptoms. A relapse was confirmed when it was accompanied by an increase of at least half a point (0.5) on the EDSS or an increase of 1 point on two different Functional Systems (FS) of the EDSS or 2 points on one of the FS (excluding Bowel/Bladder or Cerebral FS). Only descriptive statistics performed.

    Time frame: Week 0 (Day 1), Week 4, Week 8, Week 12, Week 16

  7. Number of Participants With On-Treatment Adverse Events, Serious Adverse Event, and Death

    Analysis of absolute and relative frequencies for treatment emergent Adverse Event (AE), Serious Adverse Event (SAE) and Deaths by primary System Organ Class (SOC) to demonstrate that VAY736 is safe for the treatment of patients with relapsing-remitting multiple sclerosis through the monitoring of relevant clinical and laboratory safety parameters. Only descriptive statistics performed.

    Time frame: From first dosing (single administration, Day 1) up to End of Study Visit (EOS) depending on B cell recovery (ranging from week 48 to 216)

08

Results

Posted Oct 30, 2019
Limitations and caveats
After enrolling 8 patients, the recruitment was terminated based on strategic considerations.

Participant flow

This study was conducted in 5 centers in 3 countries: Czech Republic (1), Ukraine (2 sites) and USA (2 sites).

Participant flow — Overall Study
MilestoneVAY736Placebo to VAY736
Started44
Pharmacodynamic (pd) analysis set44
Completed34
Not completed10
Withdrew: Lost to follow-up10

Outcome measures

PrimaryNumber of New T1-weighted Gadolinium (Gd)-Enhancing Lesions at Weeks 8, 12 and 16

The effect of VAY736, compared to placebo on the cumulative number of new gadolinium \[Gd\]-enhancing lesions on T1-weighted brain MRI scans in relapsing-remitting multiple sclerosis (RRMS) patient population at weeks 8, 12 and 16. Only descriptive statistics performed.

Time frame:
Week 8, Week 12, Week 16
Reported as:
Number · Lesions
Number of New T1-weighted Gadolinium (Gd)-Enhancing Lesions at Weeks 8, 12 and 16
LesionsVAY736Placebo to VAY736
Week 851
Week1252
Week 1663
SecondaryNumber of All T1-weighted Gadolinium (Gd)-Enhancing Lesions at Weeks 4, 8, 12 and 16

Magnetic resonance imaging (MRI) scanning of the brain was performed at screening/baseline, week 4, week 8, week 12 and week 16 to assess all T1-weighted Gadolinium (Gd) enhancing lesions. Each MRI scan was reviewed by a local neuro-radiologist. Only descriptive statistics performed.

Time frame:
Week 4, Week 8, Week 12, Week 16
Reported as:
Number · Lesions
Number of All T1-weighted Gadolinium (Gd)-Enhancing Lesions at Weeks 4, 8, 12 and 16
LesionsVAY736Placebo to VAY736
Week 4192
Week 8202
Week 12203
Week 16214
SecondaryNumber of New T1-weighted Gadolinium (Gd)-Enhancing Lesions at Weeks 4, 8, 12 and 16

Magnetic resonance imaging (MRI) scanning of the brain was performed at screening/baseline, week 4, week 8, week 12 and week 16 to assess all new T1-weighted Gadolinium (Gd) enhancing lesions. Each MRI scan was reviewed by a local neuro-radiologist. Only descriptive statistics performed.

Time frame:
Week 4, Week 8, Week 12, Week 16
Reported as:
Number · Lesions
Number of New T1-weighted Gadolinium (Gd)-Enhancing Lesions at Weeks 4, 8, 12 and 16
LesionsVAY736Placebo to VAY736
Week 441
Week 810
Week 1201
Week 1611
SecondaryNumber of New or Enlarging T2-weighted Gadolinium (Gd)-Enhancing Lesions at Weeks 4, 8, 12 and 16

Magnetic resonance imaging (MRI) scanning of the brain was performed at screening/baseline, week 4, week 8, week 12 and week 16 to assess T2 hyperintense lesions (new or enlarging T2-weighted lesions). Each MRI scan was reviewed by a local neuro-radiologist. Only descriptive statistics performed.

Time frame:
Week 4, Week 8, Week 12, Week 16
Reported as:
Number · Lesions
Number of New or Enlarging T2-weighted Gadolinium (Gd)-Enhancing Lesions at Weeks 4, 8, 12 and 16
LesionsVAY736Placebo to VAY736
Week 427994
Week 827793
Week 1227691
Week 1626491
SecondaryT2 Burden of Disease (Total Volume of T2-weighted Lesions) at Weeks 4, 8, 12 and 16.

Magnetic resonance imaging (MRI) scanning of the brain was performed at screening/baseline, week 4, week 8, week 12 and week 16 to assess T2 burden of disease. Each MRI scan was reviewed by a local neuro-radiologist. Only descriptive statistics performed.

Time frame:
Week 4, Week 8, Week 12, Week 16
Reported as:
Number · mm3 of T2-weighted lesions
T2 Burden of Disease (Total Volume of T2-weighted Lesions) at Weeks 4, 8, 12 and 16.
mm3 of T2-weighted lesionsVAY736Placebo to VAY736
Week 420108.917706
Week 818998.916785
Week 1218484.115996
Week 1618102.717919
SecondaryNumber of Subjects Without Any New MRI Disease Activity at Weeks 4, 8, 12 and 16.

Magnetic resonance imaging (MRI) scanning of the brain was performed at screening/baseline, week 4, week 8, week 12 and week 16 to assess patients without any new MRI disease activity (no new Gd-enhancing lesions nor new or enlarging T2 lesions). Each MRI scan was reviewed by a local neuro-radiologist. Only descriptive statistics performed.

Time frame:
Week 4, Week 8, Week 12, Week 16
Reported as:
Number · Participants
Number of Subjects Without Any New MRI Disease Activity at Weeks 4, 8, 12 and 16.
ParticipantsVAY736Placebo to VAY736
Week 442
Week 810
Week 1201
Week 1633
SecondaryProportion of Relapse-free Patients Over the 16 Weeks of the Treatment Period.

A relapse is defined as the appearance of a new neurological abnormality, or worsening of previously stable, or improving pre-existing neurological abnormality, separated by at least 30 days from the onset of a preceding clinical demyelinating event. The abnormality must be present for at least 24 hours and occur in the absence of fever (\<37.5 C) or infection. A relapse was considered confirmed when confirmed by an Extended disability status scale (EDSS)-certified physician who was not involved in the treatment of the patient, was blinded to treatment allocation, and had no access to patient medical records. It was recommended that this occurs within 5 days of the onset of symptoms. A relapse was confirmed when it was accompanied by an increase of at least half a point (0.5) on the EDSS or an increase of 1 point on two different Functional Systems (FS) of the EDSS or 2 points on one of the FS (excluding Bowel/Bladder or Cerebral FS). Only descriptive statistics performed.

Time frame:
Week 0 (Day 1), Week 4, Week 8, Week 12, Week 16
Reported as:
Count of participants · Participants
Proportion of Relapse-free Patients Over the 16 Weeks of the Treatment Period.
ParticipantsVAY736Placebo to VAY736
Week 0 (Day 1) — Relapse-free44
Week 0 (Day 1) — Relapse00
Week 4 — Relapse-free44
Week 4 — Relapse00
Week 8 — Relapse-free44
Week 8 — Relapse00
Week 12 — Relapse-free44
Week 12 — Relapse00
Week 16 — Relapse-free33
Week 16 — Relapse11
SecondaryNumber of Participants With On-Treatment Adverse Events, Serious Adverse Event, and Death

Analysis of absolute and relative frequencies for treatment emergent Adverse Event (AE), Serious Adverse Event (SAE) and Deaths by primary System Organ Class (SOC) to demonstrate that VAY736 is safe for the treatment of patients with relapsing-remitting multiple sclerosis through the monitoring of relevant clinical and laboratory safety parameters. Only descriptive statistics performed.

Time frame:
From first dosing (single administration, Day 1) up to End of Study Visit (EOS) depending on B cell recovery (ranging from week 48 to 216)
Reported as:
Count of participants · Participants
Number of Participants With On-Treatment Adverse Events, Serious Adverse Event, and Death
ParticipantsVAY736 Administered at Visit 2 (Day 1)VAY736 Administered at Visit 7 (Week 16 - Week 17)Placebo Administered at Visit 2
On-treatment Adverse Events (AEs)431
On-treatment Serious Adverse Events (SAEs)000
On-treatment Deaths000

Adverse events

Collected over Adverse events and serious adverse events were collected from first dosing (single administration, Day 1) up to End of Study Visit (EOS) depending on B cell recovery (ranging from week 48 to 216).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VAY736 Administered at Visit 2 (Day 1)0/4 (0%)0/4 (0%)4/4 (100%)
VAY736 Administered at Visit 7 (Week 16 - Week 17)0/4 (0%)0/4 (0%)3/4 (75%)
Placebo Administered at Visit 20/4 (0%)0/4 (0%)1/4 (25%)
Most frequent other events
Showing 10 of 26
Most frequent other events
EventVAY736 Administered at Visit 2 (Day 1)VAY736 Administered at Visit 7 (Week 16 - Week 17)Placebo Administered at Visit 2
TachycardiaCardiac disorders3/40/40/4
NauseaGastrointestinal disorders3/41/40/4
HeadacheNervous system disorders3/41/41/4
AstheniaGeneral disorders2/40/40/4
ChillsGeneral disorders2/40/40/4
LymphopeniaBlood and lymphatic system disorders0/41/40/4
PalpitationsCardiac disorders1/40/40/4
VomitingGastrointestinal disorders1/40/40/4
HyperthermiaGeneral disorders1/40/40/4
PyrexiaGeneral disorders1/41/40/4

Baseline characteristics

Age, Continuous
Age, Continuous(Years)VAY736Placebo to VAY736Total
Mean32.0 ± 10.4242.0 ± 2.4537.0 ± 8.82
Sex: Female, Male
Sex: Female, Male(Participants)VAY736Placebo to VAY736Total
Female235
Male213
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)VAY736Placebo to VAY736Total
Caucasian347
Other101
09

Study locations

5 sites
  • Novartis Investigative Site
    Long Beach, California 90806, United States
  • Novartis Investigative Site
    San Diego, California 92103, United States
  • Novartis Investigative Site
    Hradec Kralove, 501 03, Czechia
  • Novartis Investigative Site
    Kharkiv, 61068, Ukraine
  • Novartis Investigative Site
    Lviv, 79010, Ukraine
10

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2013 to primary completion in May 2015, 16 months.

Results were first posted in Oct 2019, 4 years 5 months after primary completion. A results delay was requested in Oct 2018.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2014
First posted
Jan 16, 2014
StartActual
Dec 20, 2013
Primary completionActual
May 5, 2015
CompletionActual
Sep 13, 2018
Results delay requested
Oct 10, 2018
Results first posted
Oct 30, 2019
Last update
Jan 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02038049
Responsible party
Sponsor
First posted
Jan 16, 2014
Start date
Dec 20, 2013
Primary completion
May 5, 2015
Completion
Sep 13, 2018
Results posted
Oct 30, 2019
Last update
Jan 5, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ianalumab

Start the discussion